PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-90.13%
Both companies show declining revenue. Martin Whitman would check for industry-wide issues.
No Data
No Data available this quarter, please select a different quarter.
-148.93%
Both companies show declining gross profit. Martin Whitman would check industry conditions.
-595.65%
Both companies show margin pressure. Martin Whitman would check industry conditions.
15.04%
R&D growth while AGEN reduces spending. John Neff would investigate strategic advantage.
33.15%
G&A growth above 1.5x AGEN's 2.74%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.43%
Operating expenses growth above 1.5x AGEN's 2.74%. Michael Burry would check for inefficiency.
20.43%
Total costs growth 1.1-1.25x AGEN's 17.19%. Bill Ackman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
3.01%
D&A growth while AGEN reduces D&A. John Neff would investigate differences.
-24.86%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
-1164.87%
Both companies show margin pressure. Martin Whitman would check industry conditions.
-24.41%
Both companies show declining income. Martin Whitman would check industry conditions.
-1160.31%
Both companies show margin pressure. Martin Whitman would check industry conditions.
-17.39%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-24.71%
Both companies show declining income. Martin Whitman would check industry conditions.
-1163.35%
Both companies show margin pressure. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-24.71%
Both companies show declining income. Martin Whitman would check industry conditions.
-1163.35%
Both companies show margin pressure. Martin Whitman would check industry conditions.
-23.33%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-23.33%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.